Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.57 |
| ▸ | FAAH | O00519 | 4/20 | 0.56 |
| ▸ | NAAA | Q02083 | 1/20 | 0.53 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.50 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.50 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.48 |
| ▸ | SELP | P16109 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19935560 | 0.92 | FAAH (0.55) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL15597179 | 0.92 | CNR1 (0.51) | CASP2FAAHNAAADNM1LPAR1 | |
| SCHEMBL12604785 | 0.90 | CASP2 (0.66) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL20996896 | 0.90 | CASP2 (0.71) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL26003367 | 0.90 | CASP2 (0.71) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL25318260 | 0.90 | CASP2 (0.71) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL22047271 | 0.90 | CASP2 (0.71) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL24812541 | 0.90 | CASP2 (0.71) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL8154588 | 0.90 | CASP2 (0.71) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL31315579 | 0.90 | CASP2 (0.71) | CASP2FAAHNAAADNM1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3858385-A2 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | Syndevrx, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-3574922-A1 | MODIFIED OR POLYMER-CONJUGATED FUMAGILLOL METAP2 INHIBITORS FOR USE IN IMPROVING OR RESTORING INSULIN SENSITIVITY | Syndevrx, Inc. (US) | 2019-12-04 | — | — | EP | disclosed |